05.01.2023 • NewsPharmaGreenfieldSustainability

Granules India and Greenko ZeroC Plan Green Pharma Zones

Granules India, a Hyderabad-based pharma company, is partnering compatriot clean energy company Greenko ZeroC to develop green zones for the sustainable manufacture of drugs and their intermediates.

The first zone will be developed in Kakinada, Andra Pradesh, where Granules will build a greenfield facility based on sustainability principles for the large-scale manufacturing of key starting materials, intermediates, APIs and fermentation-based products.    

The cost of the project, which will be implemented in phases, is estimated at $242 million over five years.

Greenko ZeroC will supply carbon-free energy, also enabling the production of green hydrogen and its various chemical derivatives, which Granules will use to make products such as dicyandiamide (DCDA), paracetamol and metformin, among others.

Anil Kumar Chalamalasetty, Greenko’s CEO and managing director, said the “innovative and pioneering partnership will propel the transformation of industrial manufacturing to be more sustainable and competitive.”

Granules India has seven manufacturing facilities in total – six are based in India (Hyderabad and Visakhapatnam) and one is in the US (Chantilly, Virginia).

Author: Elaine Burridge, Freelance Journalist

© Shutterstock/Getty Images
© Shutterstock/Getty Images

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.